NLRP1 Inflammasome Modulation Therapy for Neurodegeneration

Overview

NLRP1 (NLR family pyrin domain containing 1) is a unique inflammasome sensor that represents a fundamentally different therapeutic target from the well-studied NLRP3. Unlike NLRP3 which is primarily microglial, NLRP1 is highly expressed in neurons and directly mediates neuronal cell death through both caspase-1-dependent pyroptosis and caspase-3-dependent apoptosis. This makes NLRP1 a critical node linking neuroinflammation to irreversible neuronal loss in Alzheimer’s disease, Parkinson’s disease, and ALS.

Mechanism of Action

Neuronal Expression and Activation

NLRP1 is constitutively expressed in cortical neurons, hippocampal pyramidal cells, and dopaminergic neurons, placing it directly in the cell types most vulnerable in neurodegeneration. Unlike NLRP3 which requires priming signals, NLRP1 can be activated directly by pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and specific neuronal stressors:

• Tau pathology: Phosphorylated tau directly interacts with NLRP1, promoting inflammasome assembly in AD neurons

• Alpha-synuclein: Oligomeric α-syn binds NLRP1, triggering activation in PD

• TDP-43 pathology: Cytosolic TDP-43 aggregates activate NLRP1 in ALS/FTD

• Metabolic stress: Mitochondrial dysfunction and ATP depletion activate neuronal NLRP1

Downstream Cell Death Pathways

NLRP1 activation triggers two parallel death pathways:

1. Canonical pyroptosis via caspase-1:

   • Gasdermin B (GSDMB) cleavage

   • Pore formation and cell swelling

   • Release of pro-inflammatory IL-1β/IL-18

2. Caspase-3-dependent apoptosis via CARD cleavage:

   • Direct activation of caspase-3 (not caspase-1)

   • Apoptotic morphology without pyroptotic features

   • This pathway is unique to NLRP1 among inflammasomes

Key Molecular Interactions

flowchart TD
    A["Tau/alpha-syn/TDP-43"] --> B["NLRP1 Inflammasome Assembly"]
    B --> C{"Caspase Activation"}
    C --> D["Caspase-1 Pathway"]
    C --> E["Caspase-3 Pathway"]
    D --> F["Pyroptosis<br/>GSDMB cleavage"]
    D --> G["IL-1beta/IL-18 Release"]
    E --> H["Apoptosis"]
    H --> I["Neuronal Death"]
    F --> I
    G --> J["Chronic Neuroinflammation"]

Therapeutic Targets

Disease Coverage

Alzheimer’s Disease (8/10)

• NLRP1 activation in hippocampal neurons correlates with Braak staging

• Tau directly binds NLRP1 LRR domain

• Synergizes with microglial NLRP3 activation

• Biomarker: CSF GSDMB fragments

Parkinson’s Disease (9/10)

• Highest NLRP1 expression in dopaminergic neurons

• α-syn oligomers are potent NLRP1 activators

• Links to PINK1/Parkin mitophagy pathway

• LRRK2 G2019S synergizes with NLRP1 activation

ALS/FTD (9/10)

• TDP-43 pathology directly activates NLRP1

• C9orf72 DPR proteins trigger activation -Motor neurons are highly vulnerable to NLRP1-mediated death

Aging (7/10)

• NLRP1 expression increases with age

• Cumulative DAMPs from cellular senescence

Therapeutic Strategy

Primary Approach: Small Molecule NLRP1 Inhibitors

The most direct approach uses small molecules that block NLRP1 inflammasome assembly:

• MCC950 derivative: Modify the NLRP3-specific MCC950 for NLRP1 selectivity

• Dapansutrile (OLT1177): Already in clinical trials for inflammatory conditions; evaluate for CNS penetration

• Natural products: Explore curcumin derivatives, resveratrol analogs

Delivery Strategy

• Intranasal delivery: Bypass BBB for direct nose-to-brain delivery

• AAV-mediated expression: Express NLRP1-specific nanobodies

• Exosome-based: Engineer exosomes to carry NLRP1 siRNA

Combination Approaches

1. NLRP1 inhibitor + NLRP3 inhibitor: Dual inflammasome blockade

2. NLRP1 inhibitor + anti-aggregation: Target upstream aggregation

3. NLRP1 inhibitor + metabolic support: Address mitochondrial dysfunction

Scoring (10-Dimension Rubric)

Total: 75/100

Clinical Development Pathway

Preclinical (Years 1-2)

• In vitro: iPSC-derived neurons from AD/PD patients

• In vivo: tau transgenic mice, α-syn preformed fibrils

• Biomarker: GSDMB in CSF, neuronal NLRP1 expression

Phase 1 (Year 3)

• Safety in healthy volunteers

• PK/PD in CSF

• Dose selection for target engagement

Phase 2 (Years 4-5)

• Proof-of-concept in early AD (n=100)

• Biomarker endpoints: GSDMB, neurofilament

• Imaging: neuronal viability (MRS, PET)